News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Launches New "Race With Insulin®" Sweepstakes Asking People to Create Their Own "Pit Crew"



4/5/2013 9:41:39 AM

BIRMINGHAM, Ala., April 5, 2013 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and IZOD IndyCar Series driver Charlie Kimball today kicked off a new contest asking people to support Charlie by encouraging their friends and family to join the Race with Insulin® crew. Now through September 15, by sharing Kimball's story about the importance of team support with two or more friends or family, you can enter for a chance to win a trip to the 2013 IndyCar finale.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/61052-novo-nordisk-race-with-insulin-izod-indycar-sweepstakes-kimball-diabetes

(Logo: http://photos.prnewswire.com/prnh/20130405/MM88176)

"It takes an entire crew to help me manage both my car and my diabetes, so we can compete at the highest levels," said Kimball. "This program is a great way for people to show support, especially for friends and family affected by diabetes, and encourage them to share my story."

Kimball is the first licensed driver with diabetes to race at the highest level of the series. Diagnosed with diabetes during a routine physician's visit in 2007 while racing in Europe, he strategized with his doctor and his team to create some innovative solutions for keeping him safe and healthy on the track. Along with diet, exercise and the support of his crew, Charlie uses NovoLog® FlexPen® (insulin aspart [rDNA origin] injection) and a continuous glucose monitor to help manage his blood sugar before and during races, so that while he's in the car, he can focus on driving.

Participants can enter by going to www.RaceWithInsulin.com/crew, visiting the Race with Insulin® exhibit in the IndyCar Fan Village at select IZOD IndyCar Series races, or via mail. The grand prize winner and three friends will join Kimball's crew for a three-day/two-night trip to Southern California for the IndyCar World Championship on October 19, 2013.

The package includes round trip transportation to Los Angeles, hotel accommodations, VIP tickets to the race, and four IndyCar two-seater rides. Ten first prize winners will also receive an autographed Charlie Kimball Official die cast of Kimball's car. One Grand Prize Winner and 10 First Prize winners will be selected in a random drawing on or about September 25, 2013.

For Official Rules, visit www.racewithinsulin.com. Prize winners must meet eligibility criteria. You can also follow Charlie on Twitter at @RaceWithInsulin.

Please see updated Important Safety Information below, including use with thiazolidinediones (TZDs).

Indications and Usage
What is NovoLog® (insulin aspart [rDNA origin] injection)?

  • NovoLog® is a man-made insulin used to control high blood sugar in adults and children with diabetes mellitus.

Important Safety Information
Who should not use NovoLog®?

  • Do not use NovoLog® if your blood sugar is too low (hypoglycemia) or you are allergic to any of its ingredients.

What should I tell my health care provider before taking NovoLog®?

  • About all of your medical conditions, including liver, kidney, or heart problems.
  • If you are pregnant, breastfeeding, or plan to do either.
  • About all prescription and nonprescription medicines you take, including supplements, as your dose may need to change.

How should I take NovoLog®?

  • Eat a meal within 5 to 10 minutes after using NovoLog®, a fast-acting insulin, to avoid low blood sugar. Do not inject NovoLog® if you do not plan to eat right after your injection or bolus pump infusion.
  • Do not mix NovoLog® with any other insulin when used in a pump or with any insulin other than NPH when used with injections by syringe.
  • Do not change your dose or type of insulin unless you are told to by your health care provider.
  • Do not share needles, insulin pens, or syringes.
  • Check your blood sugar levels as directed by your health care provider.

What should I consider while using NovoLog®?

  • Alcohol, including beer and wine, may affect your blood sugar.
  • Be careful when driving a car or operating machinery. You may have difficulty concentrating or reacting if you have low blood sugar. Talk to your health care provider if you often have low blood sugar or no warning signs of low blood sugar.

What are the possible side effects of NovoLog®?

  • Low blood sugar, including when too much is taken. Some symptoms include sweating, shakiness, confusion, and headache. Severe low blood sugar can cause unconsciousness, seizures, and death.
  • Serious allergic reactions may occur. Get medical help right away, if you develop a rash over your whole body, have trouble breathing, a fast heartbeat, or sweating.
  • Other side effects include injection site reactions (like redness, swelling, and itching), skin thickening or pits at the injection site, swelling of your hands and feet, if taken with thiazolidinediones (TZDs) possible heart failure, vision changes, low potassium in your blood, and weight gain.

Please visit novolog.comfor Prescribing Information.

*Certain restrictions apply. See official rules for entry information.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global health care company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk-us.comor follow our news in the US on Twitter: @NovoNordiskUS.

About Diabetes
In the United States, 25.8 million people have diabetes, a condition in which the body does not produce enough or properly use insulin, the hormone needed to convert sugar, starches and other food into energy needed for daily life.

Race with Insulin®, NovoLog®, and FlexPen® are registered trademarks of Novo Nordisk A/S.

(c) 2013 Novo Nordisk All rights reserved. 0313-00013922-1 April 2013

SOURCE Novo Nordisk


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES